PUMA BIOTECHNOLOGY, INC. Gains (Losses) on Restructuring of Debt
PUMA BIOTECHNOLOGY, INC. (PBYI) reported Gains (Losses) on Restructuring of Debt of -$289.00 thousand for the 12-month period ending 2018-12-31, per its 10-K filed 2021-03-01.
Discontinued › Expense Statement › Operating Expenses
us-gaap:GainsLossesOnRestructuringOfDebt · last filed 2021-03-01
- PUMA BIOTECHNOLOGY, INC. gains (losses) on restructuring of debt for the quarter ending 2018-12-31 was $0.00.
- PUMA BIOTECHNOLOGY, INC. gains (losses) on restructuring of debt for the quarter ending 2018-09-30 was $0.00.
- PUMA BIOTECHNOLOGY, INC. gains (losses) on restructuring of debt for fiscal 2018 was -$289.00K.
| Period end | Gains (Losses) on Restructuring of Debt 3 month | Gains (Losses) on Restructuring of Debt 6 month | Gains (Losses) on Restructuring of Debt 9 month | Gains (Losses) on Restructuring of Debt 12 month |
|---|---|---|---|---|
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $0.00 derived: sum of 2 quarters · filed 2021-03-01 | -$289.00K 10-K · filed 2021-03-01 | |
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-07 | -$289.00K 10-Q · filed 2019-11-07 | ||
| 2018-06-30 | -$289.00K 10-Q · filed 2019-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |